AIM AIM ImmunoTech
- 0.4147
- -0.0135-3.15%
AIM ImmunoTech News
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech (AIM) said Monday that the safety evaluation of patients in the first dose level of a phase 1b/2 trial of the combination of Ampligen, or rintatolimod, and AstraZeneca's (AZN) Imfinzi,
AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it has taken an essential step forward in testing the combination of AIM's Ampligen
AIM ImmunoTech Files to Sell 9.98M Shares of Common Stock for Holders
Analytical Instrument Management Acquires PSI Laboratories
LITTLETON, Colo., April 18, 2024 /PRNewswire/ -- Analytical Instrument Management (AIM) proudly announces its acquisition of PSI Laboratories, a well-established full-service analytical laboratory ba
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data From the Study of Ampligen Combined With Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab)
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15) by 73.33 percent. This is a 188.89 percent decrease over losses of $(0.0
Earnings Call Summary | AIM ImmunoTech(AIM.US) Q4 2023 Earnings Conference
The following is a summary of the AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript:Financial Performance:AIM ImmunoTech reports having sufficient funds to continue operational and clinical a
AIM ImmunoTech Reported Cash, Cash Equivalents And Marketable Investments Of $13.1M, As Of December 31, 2023
AIM ImmunoTech Reported Cash, Cash Equivalents And Marketable Investments Of $13.1M, As Of December 31, 2023
AIM ImmunoTech GAAP EPS of -$0.60, Revenue of $0.2M
Earnings Scheduled For April 2, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. • Allego (NYSE:ALLG) is projected to report quarterly loss at $0.04 per share on reve
Navigating the Future: Aim Immunotech's Challenge Against Rapid Tech Evolution in Pharma
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indicationsCompany to host conference call and webcast today, April 2nd at 8:30 AM ET OC
AIM ImmunoTech FY 2023 Earnings Preview
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels,
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/F
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
AIM ImmunoTech Announces Publication of Positive Findings From a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") t
Analysis
Price Target
No Data
